In Europe, Medtronic and Sofinnova Launch an Accelerator

One of Europe's leading venture capital firms, Paris-based Sofinnova Partners and device industry powerhouse Medtronic Inc. have announced plans to launch a new medical device incubator or accelerator in Europe-born out of what executives at both companies see as a fundamental disconnect between the clinical and technological richness of Europe and the practical reality of starting a company there. The new organization, designed to take advantage of what both companies believe is a wealth of untapped potential for new device ideas from European physicians, is located on the campus of the École Polytechnique Fédéral de Lausanne, one of the leading technical institutes in Europe.

One of Europe's leading venture capital firms, Paris-based Sofinnova Partners and device industry powerhouse Medtronic PLC have announced plans to launch a new medical device incubator or accelerator in Europe—born out of what executives at both companies see as a fundamental disconnect between the clinical and technological richness of Europe and the practical reality of starting a company there. The new organization, designed to take advantage of what both companies believe is a wealth of untapped potential for new device ideas from European physicians, is located on the campus of the École Polytechnique FÉdÉral de Lausanne (EPFL), one of the leading technical institutes in Europe.

"If you look at the top hundred products that we sell at Medtronic--coronary stents for angioplasty, artificial discs or cardiac...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By David Wild

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By Ed Silverman

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By Marion Webb

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.